Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

NCT05711615 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05711615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05711615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
February 6, 2024
Completion date
November 3, 2026
Enrollment
30 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic dedifferentiated liposarcoma, metastatic leiomyosarcoma, metastatic myxofibrosarcoma, metastatic sarcoma, metastatic synovial sarcoma, metastatic undifferentiated pleomorphic sarcoma, unresectable dedifferentiated liposarcoma, unresectable leiomyosarcoma, unresectable myxofibrosarcoma, unresectable sarcoma, unresectable synovial sarcoma, unresectable undifferentiated pleomorphic sarcoma